About 157,523 results

ALLMedicine™ Lung Cancer Center

Research & Reviews  48,229 results

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report.
The Journal of International Medical Research; Cao X, Liu X et. al.

Jun 26th, 2022 - Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection (RET) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been...

Impacts of Built Environment on Risk of Women's Lung Cancer: A Case Study of China.
International Journal of Environmental Research and Publi... Xie H, Shao R et. al.

Jun 25th, 2022 - Built environment factors such as air pollution are associated with the risk of respiratory disease, but few studies have carried out profound investigation. We aimed to evaluate the association between the built environment and Chinese women's lu...

Beneficial Effects of Spiritual Experiences and Existential Aspects of Life Satisfactio...
https://doi.org/10.1007/s10943-022-01601-w 10.1007/BF02279928 10.1007/s10902-014-9557-9 10.1007/s10943-015-0008-7 10.1002/cncr.21865 10.1111/j.1365-2648.2004.03004.x 10.1007/s10943-019-00849-z 10.1080/073993302753429013 10.1007/s005200100289 10.1200/JCO.2011.36.2517 10.1002/pon.1556 10.1002/pon.4426 10.1080/17439760.2015.1037859 10.1080/07347330903182010 10.1002/1097-4679(196404)20:2<200::AID-JCLP2270200203>3.0.CO;2-U 10.1177/008124630903900402 10.1037/a0024402 10.1521/jscp.24.3.401.65616 10.1007/s10902-016-9787-0 10.1016/j.ejca.2009.12.014 10.1037/0003-066X.56.3.218 10.1080/02699930441000238 10.1037/rel0000202 10.1007/s11089-005-4818-y 10.1080/1047840X.2015.1092493 10.1007/s11136-020-02633-z 10.1002/pon.1424 10.1111/j.1365-2648.1992.tb01843.x 10.1007/s10865-010-9310-8 10.1080/10705519909540118 10.1007/s10943-006-9015-z 10.1002/pon.4408 10.1080/10888691.2016.1203789 10.1093/geronj/32.3.311 10.1080/10508619.2018.1556061 10.1080/17439760.2014.927902 10.1188/09.ONF.699-708 10.1046/j.1365-2648.2003.02768.x 10.1037/a0033641 10.1007/s10943-019-00907-6 10.1097/00006199-198801000-00002 10.1002/(SICI)1099-1611(199909/10)8:5<378::AID-PON406>3.0.CO;2-A 10.1188/12.ONF.E480-E488 10.1080/14330237.2014.904087 10.1080/14330237.2016.1250419 10.1080/14330237.2018.1505239 10.1111/j.1744-6198.2010.00167.x 10.3389/fonc.2015.00096 10.1111/j.1540-4560.1995.tb01321.x 10.1111/j.1758-0854.2009.01009.x 10.1002/pon.4297 10.1007/s11482-019-09802-4 10.3758/BRM.40.3.879 10.1002/pon.1386 10.1111/ecc.12152 10.1186/s12885-015-1589-y 10.1080/17439760.2015.1037858 10.1080/13607863.2013.848836 10.1002/pon.570 10.3390/rel2010029 10.1007/s11136-005-3569-1 10.1002/pon.1937 10.3390/rel12100794 10.3390/rel12110934 10.1007/s10943-012-9597-6 10.1002/pon.5155 10.3389/fpsyg.2021.769707 10.1002/pon.5155
Journal of Religion and Health; Wnuk M

Jun 25th, 2022 - Spiritual and existential issues are important factors for oncology patients' well-being. This study aimed to examine the beneficial role of spiritual experience, hope, and meaning in life for life satisfaction in patients diagnosed with breast an...

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with ...
PloS One; Jiang X, Chen J et. al.

Jun 25th, 2022 - The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China. A dynami...

Case report of sotalol Induced IgA Vasculitis.
Current Rheumatology Reviews; Mohammed BT, Alchalabi M et. al.

Jun 25th, 2022 - Background IgA vasculitis is the most common form of systemic vasculitis in children but can occur in adults. Inciting antigens include infections, drugs, foods, insect bites, and immunizations. Antibiotics and tumor necrosis factor (TNF) alpha in...

see more →

Guidelines  93 results

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Journal of Clinical Oncology : Official Journal of the Am... Daly ME, Singh N et. al.

Dec 23rd, 2021 - To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, communit...

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Ganti AKP, Loo BW et. al.

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

Updated USPSTF screening guidelines may reduce lung cancer deaths.
The Journal of Family Practice; Marshall RC, Tiglao SM et. al.

Nov 25th, 2021 - By nearly doubling the number of patients eligible for screening, as many as 60,000 US lives may be saved-but concerns may limit acceptance.

Definition and assessment of high risk in patients considered for lobectomy for stage I...
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

see more →

Drugs  212 results see all →

Clinicaltrials.gov  7,086 results

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B...

Jun 24th, 2022 - The purpose of this study is to evaluate the use of investigational agents (MK-4830, MK-5890 and Lenvatinib (MK-7902)) in combination with pembrolizumab and etoposide/platinum chemotherapy for the first-line treatment of participants with extensiv...

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Jun 24th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Jun 24th, 2022 - Background: Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive neuroendocrine cancers with poor prognosis. Although responsive to chemotherapy initially, both tumor types relapse quickly and become refractor...

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lu...

Jun 24th, 2022 - Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to d...

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Jun 24th, 2022 - The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with pembrolizumab...

see more →

News  7,335 results

Dabrafenib-Trametinib Combo Approved for Range of Solid Tumors

Jun 23rd, 2022 - The US Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with the BRAF V600E mutat...

KRAS-mutated NSCLC: Adagrasib shows favorable efficacy

Jun 22nd, 2022 - Key clinical point : Adagrasib shows favorable clinical efficacy without any new safety signals in patients with previously treated KRASG12C-mutated nonsmall cell lung cancer (NSCLC). Major finding : Among patients with measurable disease at basel.

Most favorable immune checkpoint inhibitor treatment for NSCLC

Jun 22nd, 2022 - Key clinical point : Cemiplimab appears to have the most favorable benefit-risk ratio among the analyzed immune checkpoint inhibitors (ICI) for the treatment of patients with nonsmall cell lung cancer (NSCLC). Major finding : Cemiplimab was associ.

Lung cancer screening using low-dose CT may be cost saving

Jun 22nd, 2022 - Key clinical point : A modeling study suggests that the low-dose computed tomography (LDCT) screening of high-risk adults is likely to be cost saving by shifting lung cancer diagnosis to earlier stages. Major finding : LDCT screening would lead to.

NSCLC: Are immune checkpoint inhibitors effective against brain metastases?

Jun 22nd, 2022 - Key clinical point : A meta-analysis suggests that immune checkpoint inhibitors are not very effective against brain metastases (BM) in patients with nonsmall cell lung cancer (NSCLC), except in patients with a programmed cell death-ligand 1 (PD-L.

see more →

Patient Education  54 results see all →